Global X China Biotech Innovation ETF CHB
Set alert
At close · Feb 16
- Open
- 6.70
- Prev close
- 6.64
- Mkt cap
- 1.39M
- Vol
- 154
- Avg vol
- 712
- EPS
- 0.492514
- P/E
- 13.48
- Div yield
- 0.00%
More statistics
- Low
- 6.64
- High
- 6.70
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.26
- 200-d avg
- 7.66
News
1 week ago gurufocus.com
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago(bepiro
1 week ago businesswire.com
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the…
1 week ago businesswire.com
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B…
5 months ago gurufocus.com
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligon
5 months ago accessnewswire.com
Challenger Assays Extend New Open Pittable Mineralisation
Targeting New JORC Mineral Resources at 'Challenger 3' Target HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger ‘Main', ‘Challenger West' (CW) open…
5 months ago globenewswire.com
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with…
6 months ago accessnewswire.com
Challenger West Assays Return Grades up to 60g/t Au
Shallow, high-grade mineralisation in floor of existing open pit HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger ‘Main', ‘Challenger West' (CW)…
6 months ago accessnewswire.com
First Challenger Assays Return Grades up to 170g/t Au
New zones of high-grade mineralisation identified in open pit walls HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger 'Main', 'Challenger West'…
7 months ago globenewswire.com
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with…
1 year ago globenewswire.com
Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs.
1 year ago globenewswire.com
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ…
1 year ago proactiveinvestors.co.uk
Coca-Cola HBC fizzes to new all-time high
Drinks bottler Coca-Cola HBC (ASX:CHB) saw its shares top the FTSE 100 and reach a new all-time high on Thursday morning even though it slowing in profit growth for the coming year. For the past…
2 years ago globenewswire.com
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on…